Canadian Atrial Fibrillation Anticoagulation Study "CAFA"

Completed

Phase N/A Results

Trial Description

To assess the potential of warfarin to reduce systemic thromboembolism and its inherent risk of hemorrhage.

Interventions

  • Warfarin (Coumadin┬«)Drug
    Other Names: Coumadin; Acenocoumarol
    Intervention Desc: Anticoagulant (Vitamin K antagonist)

Trial Design

Randomized, double-blind, placebo-controlled trial of 378 patients.

Patient Involvement

The target range of the international normalized ratio was 2 to 3 for the warfarin-treated patients.

Outcomes

Type Measure Time Frame Safety Issue
Primary Nonlacunar stroke, noncentral nervous systemic embolism and fatal or intracranial hemorrhage occurring within 28 days of permanent discontinuation of the study medication.